| |
|
|
|
| |
Online Extra: Preclinical Perspectives Providers look to a brighter future Contract Pharma June 2012
Earlier in the drug development process, providers are finally seeing an uptick in sponsor demand for specialized services, after paring away at excess capacity and trying to right-size preclinical operations.
Read what Nancy Gillett, corporate executive vice president and chief scientific officer at Charles River Laboratories, and other experts have commented on keeping up with this increased demand for services such as biomarkers, biosimilars, orphan drugs, as well as certain therapeutic areas.
Click here to read the full article from Contract Pharma.
|
|
Contract Pharma, Preclinical, CRO, CROs, pharmacology, biologics, biosimilars, biomarkers, biomarker, regulatory, drug discovery, drug development
Preclinical Perspectives: Providers look to a brighter future | Contract Pharma
Earlier in the drug development process, providers are finally seeing an uptick in sponsor demand for specialized services, after paring away at excess capacity and trying to right-size preclinical operations.